Lapto — Lapatinib 250 mg (150 Tablets) Heet Health Care
Lapto 250 mg (Lapatinib) is a potent targeted anticancer therapy belonging to the tyrosine kinase inhibitor class. Lapatinib is distinguished by its dual mechanism of action, simultaneously blocking both ErbB1 (EGFR) and ErbB2 (HER2) receptors. This effectively inhibits the signaling pathways responsible for the growth and proliferation of malignant cells in HER2-overexpressing tumors, slowing disease progression and metastasis.
Manufacturer: Heet Health Care. This medicinal product is a high-quality generic of the reference drug Tykerb (Tyverb). It is manufactured in compliance with international quality control standards, ensuring full bioequivalence and identical clinical efficacy to the innovator drug at a more affordable cost.
Key Features:
- ✅ Dual Target: Simultaneous inhibition of EGFR and HER2 receptors provides a more comprehensive impact on the tumor.
- ✅ Combination Therapy: Proven highly effective when used in conjunction with capecitabine, letrozole, or trastuzumab.
- ✅ Oral Administration: Convenient tablet form suitable for long-term outpatient treatment.
Lapto is prescribed for the treatment of HER2-overexpressing advanced or metastatic breast cancer:
- 🔹 In combination with capecitabine for patients who have received prior therapy including anthracyclines, taxanes, and trastuzumab.
- 🔹 In combination with aromatase inhibitors (e.g., letrozole) for postmenopausal women with hormone receptor-positive metastatic cancer.
- 🔹 In combination with trastuzumab for patients with disease progression on prior trastuzumab therapies.
Sales Unit: 1 pack containing 150 tablets, each with 250 mg of Lapatinib.
⚠️ APPLICATION INSTRUCTIONS:
- Dosage: The standard dose is typically 1250 mg (5 tablets) or 1500 mg (6 tablets) once daily, depending on the clinical protocol.
- Administration: Must be taken at least 1 hour before or 1 hour after a meal. Tablets should be swallowed whole.
- Dietary Restrictions: Avoid grapefruit and grapefruit juice, as they can significantly increase the concentration of the drug in the blood.
- Storage: Store in the original container below 30°C.
- ⛔ Cardiac Function: Pre-existing decrease in left ventricular ejection fraction (LVEF) requires careful monitoring.
- ⛔ Pregnancy: Highly hazardous to the fetus. Contraindicated during pregnancy and breastfeeding.
- ⛔ Hepatic Impairment: Severe liver dysfunction.
- Hypersensitivity to Lapatinib or any of its excipients.
Treatment requires professional medical supervision. Potential side effects include:
- 🤢 Gastrointestinal: Diarrhea (very common, requires monitoring for dehydration), nausea, and vomiting.
- 🧴 Dermatologic: Hand-foot syndrome, skin rash, and dry skin.
- 🟡 Hepatotoxicity: Elevated liver enzymes and bilirubin levels.
- 🫀 Cardiovascular: Risk of decreased left ventricular ejection fraction.
Similar products
What Customers Say
No reviews yet
Your review can be the first!